| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Phase IB/II Study of Lirilumab with Azacytidine in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
|
Daver, Naval
|
|
2017
|
17 |
10S |
p. S6-S7
2 p.
|
artikel
|
| 2 |
A Phase I/II Study of Selinexor (SEL) with Sorafenib in Patients (pts) with Relapsed and/or Refractory (R/R) FLT3 Mutated Acute Myeloid Leukemia (AML)
|
Daver, Naval
|
|
2017
|
17 |
10S |
p. S7-S8
2 p.
|
artikel
|
| 3 |
Characteristics and Outcomes of Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adult Patients: A Single-Center Experience
|
Assi, Rita
|
|
2017
|
17 |
10S |
p. S18-S19
2 p.
|
artikel
|
| 4 |
Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies
|
Rausch, Caitlin R.
|
|
2017
|
17 |
10S |
p. S4-S5
2 p.
|
artikel
|
| 5 |
Consolidation Treatment with Lenalidomide Following Front-line or Salvage Chemoimmunotherapy in Chronic Lymphocytic Leukemia
|
Strati, Paolo
|
|
2017
|
17 |
10S |
p. S12-S13
2 p.
|
artikel
|
| 6 |
Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation
|
Kim, Hee-Je
|
|
2017
|
17 |
10S |
p. S17-S18
2 p.
|
artikel
|
| 7 |
Editorial Board/Masthead
|
|
|
2017
|
17 |
10S |
p. A3-
1 p.
|
artikel
|
| 8 |
Efficacy and Safety Outcomes by Baseline Comorbidity and Age in Patients Newly Diagnosed with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Treated with Dasatinib or Imatinib in DASISION
|
Mauro, Michael J.
|
|
2017
|
17 |
10S |
p. S14-S15
2 p.
|
artikel
|
| 9 |
Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis
|
Masarova, Lucia
|
|
2017
|
17 |
10S |
p. S20-
1 p.
|
artikel
|
| 10 |
Evaluation of Fluoroquinolone Versus Other Antibiotic Prophylaxis Strategies in Adult Patients with AML Undergoing Induction Chemotherapy
|
Anderson, Telyssa
|
|
2017
|
17 |
10S |
p. S5-S6
2 p.
|
artikel
|
| 11 |
Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17p
|
Jain, Nitin
|
|
2017
|
17 |
10S |
p. S13-S14
2 p.
|
artikel
|
| 12 |
Improved Acute Graft-versus Host Disease (aGVHD) and Progression Free Survival with Post-Transplant Cyclophosphamide in AML/MDS Patients (pts) with Prior CTLA-4 or PD-1 Blockade
|
Oran, Betül
|
|
2017
|
17 |
10S |
p. S11-
1 p.
|
artikel
|
| 13 |
Intercorrelation of Expression of CD56, CD117, CD33, CD20 Antigens with Survival Rates in Patients with Multiple Myeloma in Gomel Region in Belarus
|
Kozich, Z.
|
|
2017
|
17 |
10S |
p. S19-
1 p.
|
artikel
|
| 14 |
Long-Term Outcome of Relapsed Adult Philadelphia Chromosome-Positve Acute Lymphoblastic Leukemia Treated with Continuous Imatinib Plus Combination Therapy
|
Lim, Sung Nam
|
|
2017
|
17 |
10S |
p. S1-
1 p.
|
artikel
|
| 15 |
Long-Term Outcomes of Early CP CML Patients who have Achieved CCyR but Not MMR after 24 Months on Frontline Imatinib Therapy
|
Lee, Sung-Eun
|
|
2017
|
17 |
10S |
p. S16-
1 p.
|
artikel
|
| 16 |
MCL-1 Up-Regulation through MAPK Activation Confers Acquired Resistance to BCL-2 Inhibitor ABT-199 in Pre-Clinical AML Models
|
Zhang, Qi
|
|
2017
|
17 |
10S |
p. S2-
1 p.
|
artikel
|
| 17 |
Message from the Chairmen
|
|
|
2017
|
17 |
10S |
p. A7-
1 p.
|
artikel
|
| 18 |
Molecular Pathophysiology of Myeloma and Clinical Applications
|
Anderson, Kenneth
|
|
2017
|
17 |
10S |
p. S19-
1 p.
|
artikel
|
| 19 |
Mutations of BRAF and BIRC3 Identify a Subgroup of Chronic Lymphocytic Leukemia with Very Poor Prognosis upon FCR Treatment
|
Moia, Riccardo
|
|
2017
|
17 |
10S |
p. S11-S12
2 p.
|
artikel
|
| 20 |
Nivolumab (Nivo) in Combination with Azacytidine (AZA) in Relapsed and Frontline Elderly Acute Myeloid Leukemia (AML)
|
Daver, Naval
|
|
2017
|
17 |
10S |
p. S9-
1 p.
|
artikel
|
| 21 |
Organizing Committees
|
|
|
2017
|
17 |
10S |
p. A1-A2
nvt p.
|
artikel
|
| 22 |
Outcomes with Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine as Salvage Therapy for Relapsed/Refractory Acute Myeloid Leukemia
|
Boddu, Prajwal
|
|
2017
|
17 |
10S |
p. S3-S4
2 p.
|
artikel
|
| 23 |
Phosphotyrosine-Based Phosphoproteomics of a Panel AML Cell Lines Reveals Oncogenic Signaling and Hyperactive Tyrosine Kinases as Targets for Treatment
|
van Alphen, Carolien
|
|
2017
|
17 |
10S |
p. S2-S3
2 p.
|
artikel
|
| 24 |
Randomized Phase II Study of Guadecitabine (SGI-110) Based Regimens Comparing Guadecitabine 5 days (SGI5), 10 days (SGI10), 5 days + Idarubicin (SGI5 + Ida), and 5 days + Cladribine (SGI5 + Clad), in Previously Untreated Patients ≥ 70 Years with Acute Myeloid Leukemia (AML)–a Bayesian Design
|
Naqvi, Kiran
|
|
2017
|
17 |
10S |
p. S6-
1 p.
|
artikel
|
| 25 |
Table of Contents
|
|
|
2017
|
17 |
10S |
p. A4-A6
nvt p.
|
artikel
|
| 26 |
Targeting the Mitochondria Metabolism of T-ALL with Novel Mitochondrial Complex I Inhibitor IACS-010759
|
Baran, Natalia
|
|
2017
|
17 |
10S |
p. S1-S2
2 p.
|
artikel
|
| 27 |
Targeting Unc-51 Like Autophagy Activating Kinase 1 (ULK1) in Acute Myeloid Leukemia (AML)
|
Bhattacharya, Seemana
|
|
2017
|
17 |
10S |
p. S8-S9
2 p.
|
artikel
|
| 28 |
The Combination of Quizartinib with Azacitidine or Low Dose Cytarabine is Highly Active in Patients (Pts) with FLT3-ITD Mutated Myeloid Leukemias: Interim Report of a Phase I/II Trial
|
Swaminathan, Mahesh
|
|
2017
|
17 |
10S |
p. S3-
1 p.
|
artikel
|
| 29 |
Therapy of Early Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Lower Dose Dasatinib
|
Naqvi, Kiran
|
|
2017
|
17 |
10S |
p. S15-S16
2 p.
|
artikel
|
| 30 |
Th1/17 Hybrid CD4+ Cells Are Expanded in Bronchial Alveolar Lavage Fluid from Leukemia Patients with Checkpoint Inhibitor-Induced Pneumonitis
|
Kim, Sang
|
|
2017
|
17 |
10S |
p. S10-
1 p.
|
artikel
|
| 31 |
Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Newly Diagnosed Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center
|
Masarova, Lucia
|
|
2017
|
17 |
10S |
p. S20-S21
2 p.
|
artikel
|
Tijdschrift beschrijving